Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 16, 2025
Reporting Period: Event-based report for April 16, 2025.
The filing discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding intellectual property progress. The company is incorporated in Nevada and trades on the NASDAQ under the symbol "INMB".
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing is strictly an event disclosure regarding a patent application.
Material Changes
Intellectual Property Update: On April 16, 2025, the Company received a favorable patentability opinion from the United States Patent and Trademark Office (USPTO), acting as the International Search Authority. This opinion covers all claims in the Company's international patent application (PCT/US25/17028).
Subject Matter: The application is titled "THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS."
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) but does not include specific forward-looking guidance, financial outlook, or management commentary within the text of the 8-K itself.
Risks and Contingencies: The filing notes that the information provided is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it subject to liabilities under Sections 11 and 12(a)(2) of the Securities Act. It explicitly states the information shall not be incorporated by reference into other filings unless expressly set forth.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed context on the patent opinion.
- Confirm the status of the international patent application PCT/US25/17028 in USPTO databases.
- Review the Company's most recent 10-K or 10-Q for current financial position, as this 8-K contains no financial data.
- Assess the strategic importance of "pooled, culture-expanded human umbilical cord derived mesenchymal stromal cells" to the Company's pipeline.